StockData

Scienture vs XTL Biopharmaceuticals

SCNX and XTLB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SCNX and XTLB compare

Scienture scores higher on the StockData Score (3 against 0 for XTL Biopharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSCNXXTLB
Size and price
Market cap$123M–
Share price$2.99$1.54
Change, 1 year−82.2%−59.1%
Change, 5 years−99.8%−87.1%
Beta (5Y)1.071.21
Employees83
StockData Score
Total score3 (better)0
Valuation score1 (better)0
Growth score00
Performance score1 (better)0
Health score1 (better)0
Dividend score00
Valuation
P/B1.9×–
Growth
Revenue growth, 5Y average−52.1%–
Profitability
Return on equity−53.5%–
Return on invested capital−47.3%–
Financial health
Interest coverage−13.1×−6.3× (better)
Current ratio3.04–
Altman Z-score0.31–
Piotroski F-score4–
Dividends and buybacks
Shareholder yield0.00%–
Ownership
Held by institutions–0.00%
Held by insiders16.6%0.00%
Short interest, % of float0.34%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.